EUVIMEDEUVIMED entdecken
Open Access

Improvements in Walking Distance during Nusinersen Treatment – A Prospective 3-year SMArtCARE Registry Study

Astrid Pechmann, Max Behrens, Katharina Dörnbrack, Adrian Tassoni, Franziska Wenzel, Sabine Stein, Sibylle Vogt, Daniela Zöller, Günther Bernert, Tim Hagenacker, Ulrike Schara-Schmidt, Maggie C Walter und 38 weitere

Journal of Neuromuscular Diseases · 2023

DOI: 10.3233/jnd-221600 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuromuscular Diseases, 2023. Verfasst von Astrid Pechmann und 49 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropediatrics and Muscle Disorders, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, G…. Hauptthemen laut MEDLINE: Spinal Muscular Atrophies of Childhood, Muscular Atrophy, Spinal. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives: Disease progression in patients with spinal muscular atrophy (SMA) has changed dramatically within the past years due to the approval of three different disease-modifying treatments. Nusinersen was the first drug to be approved for the treatment of SMA patients. Clinical trials provided data from infants with SMA type 1 and children with SMA type 2, but there is still insufficient evidence and only scarcely reported long-term experience for nusinersen treatment in ambulant patients. Here, we report data from the SMArtCARE registry of ambulant patients under nusinersen treatment with a follow-up period of up to 38 months.

Methods

SMArtCARE is a disease-specific registry in Germany, Austria and Switzerland. Data are collected as real-world data during routine patient visits. Our analysis included all patients under treatment with nusinersen able to walk independently before start of treatment with focus on changes in motor function.

Results

Data from 231 ambulant patients were included in the analysis. During the observation period, 31 pediatric walkers (27.2%) and 31 adult walkers (26.5%) experienced a clinically meaningful improvement of≥30 m in the 6-Minute-Walk-Test. In contrast, only five adult walkers (7.7%) showed a decline in walking distance≥30 m, and two pediatric walkers (1.8%) lost the ability to walk unassisted under treatment with nusinersen. HFMSE and RULM scores improved in pediatric and remained stable in adult patients.

Conclusion

Our data demonstrate a positive effect of nusinersen treatment in most ambulant pediatric and adult SMA patients. We not only observed a stabilization of disease progression or lack of deterioration, but clinically meaningful improvements in walking distance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spinal Muscular Atrophies of ChildhoodMuscular Atrophy, SpinalInfantAdultChildHumansProspective StudiesWalkingRegistriesDisease ProgressionOligonucleotides

Stichwörter der Autor:innen

SMArtCARESpinal muscular atrophyambulantnusinersenwalker

Substanzen

nusinersenOligonucleotides

Autor:innen und Institutionen

  • Department of Neuropediatrics and Muscle Disorders, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany.
  • Clinical Trials Unit, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Clinic Favoriten, Department of Pediatrics, Vienna, Austria.
  • Department of Neurology, and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, Essen, Germany.
  • Department of Neuropediatrics and Neuromuscular Centre for children and Adolescents, Center for Translational Neuro- and Behavioral Sciences, University of Duisburg-Essen, Essen, Germany.

Zitieren

APA

Pechmann, A., Behrens, M., Dörnbrack, K., Tassoni, A., Wenzel, F., Stein, S., Vogt, S., Zöller, D., Bernert, G., Hagenacker, T., Schara-Schmidt, U., Walter, M. C., Steinbach, M., Blaschek, A., Baumann, M., Baumgartner, M., Becker, B., Flotats-Bastardas, M., Friese, J., …, & SMArtCARE Study Group (2023). Improvements in Walking Distance during Nusinersen Treatment – A Prospective 3-year SMArtCARE Registry Study. Journal of Neuromuscular Diseases. https://doi.org/10.3233/jnd-221600

Vancouver

Pechmann A, Behrens M, Dörnbrack K, Tassoni A, Wenzel F, Stein S, et al. Improvements in Walking Distance during Nusinersen Treatment – A Prospective 3-year SMArtCARE Registry Study. Journal of Neuromuscular Diseases. 2023. doi:10.3233/jnd-221600

BibTeX
@article{Pechmann2023,
  author = {Pechmann, Astrid and Behrens, Max and Dörnbrack, Katharina and Tassoni, Adrian and Wenzel, Franziska and Stein, Sabine and Vogt, Sibylle and Zöller, Daniela and Bernert, Günther and Hagenacker, Tim and Schara-Schmidt, Ulrike and Walter, Maggie C and Steinbach, Meike and Blaschek, Astrid and Baumann, Matthias and Baumgartner, Manuela and Becker, Benedikt and Flotats-Bastardas, Marina and Friese, Johannes and Günther, Rene and Hahn, Andreas and Küpper, Hanna and Johannsen, Jessika and Kamm, Christoph and Koch, Jan Christoph and Köhler, Cornelia and Kölbel, Heike and Kolzter, Kirsten and von Moers, Arpad and Naegel, Steffen and Neuwirth, Christoph and Petri, Susanne and Rödiger, Annekathrin and Schimmel, Mareike and Schrank, Bertold and Schreiber, Gudrun and Smitka, Martin and Stadler, Christian and Steiner, Elisabeth and Stögmann, Eva and Trollmann, Regina and Türk, Matthias and Weiler, Markus and Stoltenburg, Corinna and Willichowsky, Ekkehard and Zeller, Daniel and Ziegler, Andreas and Lochmüller, Hanns and Kirschner, Janbernd and SMArtCARE Study Group, SMArtCARE Study Group},
  title = {Improvements in Walking Distance during Nusinersen Treatment – A Prospective 3-year SMArtCARE Registry Study},
  journal = {Journal of Neuromuscular Diseases},
  year = {2023},
  doi = {10.3233/jnd-221600}
}
Kostenlos starten →